Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Monday's Pre-Market Insights: CLDX, CLDN, CTIC, TGTX

Published 06/01/2015, 08:27 AM
Updated 05/14/2017, 06:45 AM


Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares rose more than +10% in pre-market trading to $32.01 after the biopharmaceutical company released data on a study indicating that an experimental vaccine was effective in patients with brain cancer. The 12-month consensus target price on TipRanks for Celldex is $37.23, marking a 29% potential upside based on current levels. Out of the 4 analysts who cover Celldex stock, all of them have open Buy positions.


Celladon Corp (NASDAQ:CLDN) shares are up more than +11% to $2.58 in pre-market trading following an announcement of approval for a strategic plan to begin the process to seek an acquisition or a partnership. The Board of Directors believes this is the best way to maximize value for shareholders. According to TipRanks, two top ranked analysts have Hold ratings on the stock with an average price target of $3, representing a nearly 30% upside from where the stock is currently trading.


CTI BioPharma Corp (NASDAQ:CTIC) shares increased +7.7% in pre-market trading to $2.09 on Monday morning after the biopharmaceutical company announced clinically meaningful results for its Phase 3 Pacritinib Study results, a therapy for a rare bone marrow cancer. According to TipRanks, Debjit Chattopadhyay of Roth Capital reiterated a Buy rating on CTIC in late March as he expected positive results from the test.


TG Therapeutics Inc (NASDAQ:TGTX) shares are up +7.75% to $16.96 after the biopharmaceutical company posted positive clinical results from two ongoing studies of a combination drug and an independent drug. The combination was well tolerated in all 55 patients enrolled in the study. CEO Michael Weiss noted, “We continue to be impressed with the safety and efficacy profile of TGR-1202, as a single agent, and in combination with TG-1101, and we believe the high level of activity and our differentiated safety profile seen to date.” According to TipRanks, two top-ranked analysts currently have Buy ratings on the stock with an average price target of $27.50, marking a 74% upside from where the stock is currently trading.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.